Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pak Fah Yeow InternationalHKSE:00239 80 EBITDA Margin % is 52.47% as of Dec. 2025, which is 29% above its 10-year median of 40.58. GuruFocus rates HKSE:00239 with a GF Score™ of 80/100 and a GF Value™ of HK$2.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Pak Fah Yeow International ranks better than 97.09% on this metric.
Pak Fah Yeow International (HKSE:00239) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pak Fah Yeow International EBITDA Margin % Related Terms
Pak Fah Yeow International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pak Fah Yeow International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pak Fah Yeow International EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pak Fah Yeow International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pak Fah Yeow International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pak Fah Yeow International (HKSE:00239) has a EBITDA Margin % of 52.47% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pak Fah Yeow International and its competitors. This is 29% above median its historical median of 40.58. According to the industry distribution chart, Pak Fah Yeow International ranks #28 out of 961 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Pak Fah Yeow International's EBITDA Margin % too high?
Pak Fah Yeow International's current EBITDA Margin % of 52.47% is 29% above median its 10-year median of 40.58. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Pak Fah Yeow International's value of 52.47% is 323.5% above this industry median. Based on the distribution chart, Pak Fah Yeow International ranks #28 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pak Fah Yeow International has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pak Fah Yeow International's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pak Fah Yeow International ranks #28 out of 961 companies for EBITDA Margin %. This places Pak Fah Yeow International in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Pak Fah Yeow International's value of 52.47% is 323.5% above this benchmark. While the company's 10-year median is 40.58 vs. the industry median of 12.39, Pak Fah Yeow International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pak Fah Yeow International's current EBITDA Margin % of 52.47% is 323.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pak Fah Yeow International and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pak Fah Yeow International's current EBITDA Margin % is 52.47%, which is 29% above median its own 10-year median of 40.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pak Fah Yeow International stock overvalued right now?
Based on GuruFocus' analysis, Pak Fah Yeow International (HKSE:00239) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.17, compared to a current price of HK$2.38 — trading 9.4% above its estimated fair value. The current EBITDA Margin % is 52.47%, which is 29% above median its 10-year median of 40.58 and 323.5% above the Drug Manufacturers industry median of 12.39. Pak Fah Yeow International's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pak Fah Yeow International (HKSE:00239), the current EBITDA Margin % is 52.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pak Fah Yeow International (HKSE:00239) Overvalued in 2026?
Based on GuruFocus' analysis, Pak Fah Yeow International stock appears to be overvalued.
The current stock price of HK$2.38 is trading 9.4% above its estimated GF Value™ of HK$2.17.
GuruFocus considers Pak Fah Yeow International to be Fairly Valued.
Key valuation signals for HKSE:00239:
EBITDA Margin %: 52.47% (29% above median its 10-year median of 40.58)
GF Value™: HK$2.17 vs. price of HK$2.38 (9.4% above fair value)
Industry Position: 323.5% above the Drug Manufacturers median (#28 of 961)
No single metric tells the full story. See the HKSE:00239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pak Fah Yeow International Ltd, with its subsidiaries, is engaged in the manufacture and distribution of healthcare products, including Hoe Hin branded products. It also engages in real estate investment and treasury investment businesses. It has three business segments, namely healthcare, property investments, and treasury investments. The Company derives the majority of its revenues from the Healthcare segment.The Groups businesses cover Hong Kong, Macau, other regions in the Peoples Republic of China (the PRC or Chinese Mainland), Southeast Asia, North America and the United Kingdom.
80GF Score
Get the complete analysis for HKSE:00239
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00239 has been successfully added to your 
